IBALGIN DUO EFFECT
50MG/G+2MG/G CRM 50G
SÚKL code | 0207891 |
---|---|
Name of the product | IBALGIN DUO EFFECT |
_MA_MEDICATION_DETAIL_INFO_MED_NAME i | IBALGIN DUO EFFECT |
Supplement | 50MG/G+2MG/G CRM 50G |
Strenght | 50MG/G+2MG/G |
Pharmaceutical form | Cream |
Package | 50G |
Route | Cutaneous use |
Language of the pack | Czech |
Wrap type | Tube |
Legal status | OTC medicinal products |
Active substance |
IBUPROFEN (IBUPROFENUM) HEPARINOIDE S (HEPARINOIDUM S) |
ATC group | M02AA13 |
ATC group name | IBUPROFEN |
Marketing authorisation information
Registration Number | 29/ 695/99-C |
---|---|
Type of MA | National |
MA status | B - medicinal product after change, may be placed on the market for the period of 6 months (Placed on the market till) and used until expiration, not later than till the end of validity of the marketing authorisation (Valid till) |
Placed on the market till | 31. 12. 2021 |
MA Holder | sanofi-aventis, s.r.o., Praha |
MA Holder country | ČESKÁ REPUBLIKA |
Actual MA holder | Opella Healthcare Czech s.r.o., Praha |
Actual MA holder country | ČESKÁ REPUBLIKA |